echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Oncologist: Efficacy and safety of Pembrolizumab (pembrolizumab) combined with CAPOX (oxaliplatin + capecitabine) in advanced cholangiocarcinoma (BTC)

    Oncologist: Efficacy and safety of Pembrolizumab (pembrolizumab) combined with CAPOX (oxaliplatin + capecitabine) in advanced cholangiocarcinoma (BTC)

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the journal Oncologist published the results of a phase II clinical study evaluating the use of the PD-1 inhibitor pembrolizumab (pembrolizumab) in combination with CAPOX (oxaliplatin + capecitabine) in advanced cholangiocarcinoma (BTC).
    Efficacy and safety of treatment
    .

    Recently, the journal Oncologist published the results of a phase II clinical study evaluating the use of the PD-1 inhibitor pembrolizumab (pembrolizumab) in combination with CAPOX (oxaliplatin + capecitabine) in advanced cholangiocarcinoma (BTC).
    Efficacy and safety of treatment
    .

    The patients studied were histologically confirmed BTC, pembrolizumab + oxaliplatin d1, capecitabine bid d1-d14 for 6 cycles


    .


    The patients studied were histologically confirmed BTC, pembrolizumab + oxaliplatin d1, capecitabine bid d1-d14 for 6 cycles


    The study included 11 patients, with a median age of 67 years (51-81 years), and 55% of patients were women


    PD patients received an average of 5.


    The median progression-free survival was 4.


    1 months (95% CI: 2.


    The median progression-free survival was 4.


    The most common grade 3 and 4 adverse events were decreased lymphocyte count (64%), anemia (36%), decreased platelet count (27%), and hyponatremia (27%)


    .


    The most common grade 3 and 4 adverse events were decreased lymphocyte count (64%), anemia (36%), decreased platelet count (27%), and hyponatremia (27%)


    In conclusion, the study shows that capecitabine + oxaliplatin combined with pembrolizumab is tolerable and is a potentially effective treatment for refractory advanced BTC


    .


    In conclusion, the study shows that capecitabine + oxaliplatin combined with pembrolizumab is tolerable and is a potentially effective treatment for refractory advanced BTC


    Original source:

    Cecilia Monge, Erica C.


    Pehrsson, Changqing Xie, et al.


    Cecilia Monge, Erica C.
    Pehrsson, Changqing Xie, et al.
    A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.
    The Oncologist, 2022, 27, e273–e285.
    https: https://doi.
    org/10.
    1093/oncolo/oyab073
    .
      https://doi.
    org/10.
    1093/oncolo/oyab073
    https://doi.
    org/10.
    1093/oncolo/oyab073 .
    .
    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.